메뉴 건너뛰기




Volumn 16, Issue 1, 2006, Pages 77-82

Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer

Author keywords

Chemotherapy; Epirubicin; Ifosfamide; Relapsed advanced ovarian cancer

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; MESNA; PLATINUM; TAXANE DERIVATIVE;

EID: 33645344104     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00288.x     Document Type: Article
Times cited : (6)

References (36)
  • 1
    • 0036711606 scopus 로고    scopus 로고
    • Part I: Chemotherapy for epithelial ovarian cancer-treatment at first diagnosis
    • Harries M Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002 3 529 36.
    • (2002) Lancet Oncol , vol.3 , pp. 529-36
    • Harries, M.1    Gore, M.2
  • 2
    • 0036714217 scopus 로고    scopus 로고
    • Part II: Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease
    • Harries M Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 2002 3 537 45.
    • (2002) Lancet Oncol , vol.3 , pp. 537-45
    • Harries, M.1    Gore, M.2
  • 3
    • 0142053372 scopus 로고    scopus 로고
    • Current status of taxane and platinum-based chemotherapy in ovarian cancer
    • McGuire WP. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol 2003 21 Suppl. 10 133 5.
    • (2003) J Clin Oncol , vol.21 , Issue.10 SUPPL. , pp. 133-5
    • McGuire, W.P.1
  • 4
    • 1542364058 scopus 로고    scopus 로고
    • Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC). a GINECO study [abstract]
    • Abstract 829
    • Pujade Lauraine E Paraiso D Curé H et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC). A GINECO study [abstract]. Proc Am Soc Clin Oncol 2002 21 208a. Abstract 829.
    • (2002) Proc Am Soc Clin Oncol , vol.21
    • Pujade Lauraine, E.1    Paraiso, D.2    Curé, H.3
  • 6
    • 0242319868 scopus 로고    scopus 로고
    • Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma
    • A multicenter GINECO, phase II study
    • Guastalla JP Pujade Lauraine E Weber B et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO, phase II study. Ann Oncol 1998 9 37 43.
    • (1998) Ann Oncol , vol.9 , pp. 37-43
    • Guastalla, J.P.1    Pujade Lauraine, E.2    Weber, B.3
  • 7
    • 0036499282 scopus 로고    scopus 로고
    • Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: Application toward a dynamic disease state model of ovarian cancer
    • Dizon DS Hensley ML Poynor EA et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002 20 1238 47.
    • (2002) J Clin Oncol , vol.20 , pp. 1238-47
    • Dizon, D.S.1    Hensley, M.L.2    Poynor, E.A.3
  • 8
    • 1242342740 scopus 로고    scopus 로고
    • The role of anthracyclines in second-line therapy of ovarian cancer
    • Vermoken JB. The role of anthracyclines in second-line therapy of ovarian cancer. Int J Gynecol Cancer 2003 13 Suppl. 2 178 84.
    • (2003) Int J Gynecol Cancer , vol.13 , Issue.2 SUPPL. , pp. 178-84
    • Vermoken, J.B.1
  • 9
    • 0024422604 scopus 로고
    • Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A GOG Study
    • Sutton GP Blessing JA Homesley HD et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a GOG Study. J Clin Oncol 1989 7 1672 6.
    • (1989) J Clin Oncol , vol.7 , pp. 1672-6
    • Sutton, G.P.1    Blessing, J.A.2    Homesley, H.D.3
  • 10
    • 0026599140 scopus 로고
    • Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
    • Markman M Hakes T Reichman B et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992 10 243 8.
    • (1992) J Clin Oncol , vol.10 , pp. 243-8
    • Markman, M.1    Hakes, T.2    Reichman, B.3
  • 11
    • 0030525353 scopus 로고    scopus 로고
    • Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer
    • Dorval T Soussain C Beuzeboc P et al. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. J Infus Chemother 1996 6 47 9.
    • (1996) J Infus Chemother , vol.6 , pp. 47-9
    • Dorval, T.1    Soussain, C.2    Beuzeboc, P.3
  • 12
    • 0025346817 scopus 로고
    • Ifosfamide given as 24 h infusion with mesna in patients with recurrent ovarian cancer: Preliminary results
    • Willemse PH van der Burg ME van der Gaast A et al. Ifosfamide given as 24 h infusion with mesna in patients with recurrent ovarian cancer: preliminary results. Cancer Chemother Pharmacol 1990 26 51 4.
    • (1990) Cancer Chemother Pharmacol , vol.26 , pp. 51-4
    • Willemse, P.H.1    Van Der Burg, M.E.2    Van Der Gaast, A.3
  • 13
    • 0000381874 scopus 로고    scopus 로고
    • Cyclophosphamide, adriamycin, cisplatin in recurrent platinum sensitive ovarian cancer: A randomised phase II study [abstract]
    • Abstract 751
    • Colombo N. Cyclophosphamide, adriamycin, cisplatin in recurrent platinum sensitive ovarian cancer: a randomised phase II study [abstract]. Proc Am Soc Clin Oncol 1996 15 279. Abstract 751.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 279
    • Colombo, N.1
  • 14
    • 0003215792 scopus 로고    scopus 로고
    • A randomized study in recurrent ovarian cancer comparing the efficacy of single agent versus combination chemotherapy according to time to relapse [abstract]
    • Abstract 750
    • Bolis G Scarfone G Villa A et al. A randomized study in recurrent ovarian cancer comparing the efficacy of single agent versus combination chemotherapy according to time to relapse [abstract]. Proc Am Soc Clin Oncol 1996 15 279. Abstract 750.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 279
    • Bolis, G.1    Scarfone, G.2    Villa, A.3
  • 15
    • 0036498921 scopus 로고    scopus 로고
    • Randomized controlled trial of single agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first line platinum based regimen
    • Cantu MG Buda A Parma G et al. Randomized controlled trial of single agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first line platinum based regimen. J Clin Oncol 2002 20 1232 7.
    • (2002) J Clin Oncol , vol.20 , pp. 1232-7
    • Cantu, M.G.1    Buda, A.2    Parma, G.3
  • 16
    • 0033976336 scopus 로고    scopus 로고
    • Ifosfamide-based drug combinations: Preclinical evaluation of drug interactions and translation into clinic
    • Vanhoefer U Schleucher N Klaassen U et al. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into clinic. Semin Oncol 2000 27 8 13.
    • (2000) Semin Oncol , vol.27 , pp. 8-13
    • Vanhoefer, U.1    Schleucher, N.2    Klaassen, U.3
  • 18
    • 0029759230 scopus 로고    scopus 로고
    • Epirubicin and ifosfamide in metastatic breast cancer
    • Becher R Kloke O Hayungs J et al. Epirubicin and ifosfamide in metastatic breast cancer. Semin Oncol 1996 23 Suppl. 7 28 33.
    • (1996) Semin Oncol , vol.23 , Issue.7 SUPPL. , pp. 28-33
    • Becher, R.1    Kloke, O.2    Hayungs, J.3
  • 19
    • 0025278347 scopus 로고
    • Ifosfamide combination chemotherapy in advanced breast cancer
    • Schmid H Kaufman M Grischke EM et al. Ifosfamide combination chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol 1990 26 Suppl S71 3.
    • (1990) Cancer Chemother Pharmacol , vol.26 , Issue.SUPPL. , pp. 71-3
    • Schmid, H.1    Kaufman, M.2    Grischke, E.M.3
  • 20
    • 0028338769 scopus 로고
    • Case report: Treatment of primary ovarian angiosarcoma with ifosfamide and doxorubicin
    • Cunningham MJ Brooks JS Noumoff JS. Case report: treatment of primary ovarian angiosarcoma with ifosfamide and doxorubicin. Gynecol Oncol 1994 53 265 8.
    • (1994) Gynecol Oncol , vol.53 , pp. 265-8
    • Cunningham, M.J.1    Brooks, J.S.2    Noumoff, J.S.3
  • 21
    • 0030017940 scopus 로고    scopus 로고
    • Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer
    • Marzola M Parma G Bonazzi C et al. Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. Ann Oncol 1996 7 419 21.
    • (1996) Ann Oncol , vol.7 , pp. 419-21
    • Marzola, M.1    Parma, G.2    Bonazzi, C.3
  • 22
    • 0029893575 scopus 로고    scopus 로고
    • A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer
    • Nardi M Giulia MD Pollera CF et al. A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 1996 38 298 301.
    • (1996) Cancer Chemother Pharmacol , vol.38 , pp. 298-301
    • Nardi, M.1    Giulia, M.D.2    Pollera, C.F.3
  • 23
    • 0030039147 scopus 로고    scopus 로고
    • Defining progression of ovarian carcinoma during follow-up according to CA125: A North Thames Ovary Group study
    • Rustin GJ Nelstrop AE Tuxen MK et al. Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group study. Ann Oncol 1996 7 361 4.
    • (1996) Ann Oncol , vol.7 , pp. 361-4
    • Rustin, G.J.1    Nelstrop, A.E.2    Tuxen, M.K.3
  • 24
    • 0035879099 scopus 로고    scopus 로고
    • Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    • Gordon AN Fleagle JT Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001 15 3312 22.
    • (2001) J Clin Oncol , vol.15 , pp. 3312-22
    • Gordon, A.N.1    Fleagle, J.T.2    Guthrie, D.3
  • 25
    • 0030900145 scopus 로고    scopus 로고
    • Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
    • ten Bokkel Huinink W Gore M Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997 15 2177 80.
    • (1997) J Clin Oncol , vol.15 , pp. 2177-80
    • Ten Bokkel Huinink, W.1    Gore, M.2    Carmichael, J.3
  • 26
    • 0024334410 scopus 로고
    • The effect of ifosfamide and its metabolites on intracellular glutathione level in vitro and in vivo
    • Lind MJ McGown AT Hadfield JA et al. The effect of ifosfamide and its metabolites on intracellular glutathione level in vitro and in vivo. Biochem Pharmacol 1989 38 1835 40.
    • (1989) Biochem Pharmacol , vol.38 , pp. 1835-40
    • Lind, M.J.1    McGown, A.T.2    Hadfield, J.A.3
  • 27
    • 0025962117 scopus 로고
    • Increased glutathione peroxidase activity in a human sarcoma cell line with doxorubicin resistance
    • Samuels BL Murray JL Cohen MB et al. Increased glutathione peroxidase activity in a human sarcoma cell line with doxorubicin resistance. Cancer Res 1991 51 521 7.
    • (1991) Cancer Res , vol.51 , pp. 521-7
    • Samuels, B.L.1    Murray, J.L.2    Cohen, M.B.3
  • 28
    • 0032144047 scopus 로고    scopus 로고
    • Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent
    • Markman M Kennedy A Sutton G et al. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 1998 70 272 4.
    • (1998) Gynecol Oncol , vol.70 , pp. 272-4
    • Markman, M.1    Kennedy, A.2    Sutton, G.3
  • 29
    • 0025194258 scopus 로고
    • Epirubicin for pretreated advanced ovarian cancer
    • Coleman R Towlson K Wiltshaw E et al. Epirubicin for pretreated advanced ovarian cancer. Eur J Cancer 1990 26 850 1.
    • (1990) Eur J Cancer , vol.26 , pp. 850-1
    • Coleman, R.1    Towlson, K.2    Wiltshaw, E.3
  • 30
    • 0029950202 scopus 로고    scopus 로고
    • Phase II trial of epirubicin at standard dose in relapsed ovarian cancer
    • Palaez I Lacave AJ Palacio I et al. Phase II trial of epirubicin at standard dose in relapsed ovarian cancer. Eur J Cancer 1996 32A 899 900.
    • (1996) Eur J Cancer , vol.32 , pp. 899-900
    • Palaez, I.1    Lacave, A.J.2    Palacio, I.3
  • 31
    • 0036198668 scopus 로고    scopus 로고
    • Ifosfamide and Vinorelbine in advanced platinum-resistant ovarian cancer: Excessive toxicity with a potentially active regimen
    • Gonzalez-Martin A Crespo C Garcia-Lopez JL et al. Ifosfamide and Vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen. Gynecol Oncol 2002 84 368 73.
    • (2002) Gynecol Oncol , vol.84 , pp. 368-73
    • Gonzalez-Martin, A.1    Crespo, C.2    Garcia-Lopez, J.L.3
  • 32
    • 0026476151 scopus 로고
    • The enigma of ifosfamide encephalopathy
    • Cerny T Kupfer A. The enigma of ifosfamide encephalopathy. Ann Oncol 1992 3 679 81.
    • (1992) Ann Oncol , vol.3 , pp. 679-81
    • Cerny, T.1    Kupfer, A.2
  • 34
    • 0025307207 scopus 로고
    • Ifosfamide and mesna: Response and toxicity at standard and high dose schedules
    • Antman KH Elias A Ryan L. Ifosfamide and mesna: response and toxicity at standard and high dose schedules. Semin Oncol 1990 17 Suppl. 4 68 73.
    • (1990) Semin Oncol , vol.17 , Issue.4 SUPPL. , pp. 68-73
    • Antman, K.H.1    Elias, A.2    Ryan, L.3
  • 35
    • 0035879099 scopus 로고    scopus 로고
    • Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    • Gordon AN Fleagle JT Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001 3312 22.
    • (2001) J Clin Oncol , pp. 3312-22
    • Gordon, A.N.1    Fleagle, J.T.2    Guthrie, D.3
  • 36
    • 0008810987 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin (Caelyx) and ifosfamide (IFEX) in recurrent ovarian cancer (ROC): A phase I/II Gineco study [abstract]
    • Abstract 1577
    • Bourgeois H Curé H Guastalla JP et al. Pegylated liposomal doxorubicin (Caelyx) and ifosfamide (IFEX) in recurrent ovarian cancer (ROC): a phase I/II Gineco study [abstract]. Proc Am Soc Clin Oncol 2000 19 398a. Abstract 1577.
    • (2000) Proc Am Soc Clin Oncol , vol.19
    • Bourgeois, H.1    Curé, H.2    Guastalla, J.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.